Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5302174 | 0.82 | AHR (0.53) | CYP3A4FLT1AHRCRHBPCRHR2 | |
| SCHEMBL30787730 | 0.82 | AHR (0.53) | CYP3A4FLT1AHRCRHBPCRHR2 | |
| SCHEMBL4133359 | 0.73 | CYP3A4 (0.38) | CYP3A4FLT1AHRCRHBPCRHR2 | |
| SCHEMBL15893452 | 0.73 | GAA (0.52) | CYP3A4FLT1AHRCRHBPCRHR2 | |
| SCHEMBL4016972 | 0.71 | CYP3A4 (0.37) | CYP3A4ABCG2MAPTKMT2AMEN1 | |
| SCHEMBL8524080 | 0.71 | AHR (0.62) | CYP3A4FLT1AHRCRHBPCRHR2 | |
| SCHEMBL30456979 | 0.71 | AHR (0.62) | CYP3A4FLT1AHRCRHBPCRHR2 | |
| SCHEMBL2022289 | 0.71 | CD44 (0.46) | CYP3A4FLT1AHRMAPTKMT2A | |
| SCHEMBL772742 | 0.71 | CYP3A4 (0.46) | CYP3A4FLT1AHRKMT2AMEN1 | |
| SCHEMBL9871731 | 0.71 | MEN1 (0.40) | CYP3A4AHRABCG2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | claimed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | claimed |
| US-7934888-B2 | Marine anti-foulant system and methods for using same | VIV SUPPRESSION, INC. (US) | 2011-05-03 | — | — | US | claimed |
| CN-101827838-A | Cannabinoid receptor ligand | ASTRAZENECA AB | 2010-09-08 | — | — | CN | claimed |
| EP-2190838-A1 | CANNABINOID RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2010-06-02 | — | — | EP | claimed |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | claimed |
| US-20090185867-A1 | MARINE ANTI-FOULANT SYSTEM AND METHODS FOR USING SAME | ASSET INTEGRITY MANAGEMENT SOLUTIONS, L.L.C., D/B/A AIMS INTERNATIONAL | 2009-07-23 | — | — | US | claimed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | claimed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| CN-101175754-A | Novel tetrahydro-1H-pyrido [4, 3-b ] indole derivatives as CB1 receptor ligands | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | CN | claimed |
| EP-0766665-A2 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-04-09 | — | — | EP | claimed |
| EP-0766664-A2 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-04-09 | — | — | EP | claimed |
| WO-1995035275-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| WO-1995035276-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| US-5441743-A | In thermoplastic or thermosetting binder | BATTELLE MEMORIAL INSTITUTE (US) | 1995-08-15 | — | — | US | claimed |
| EP-0449975-A1 | NON-TIN-BASED, LOW TOXICITY ANTI-FOULING AGENTS. | BATTELLE MEMORIAL INSTITUTE (US) | 1991-10-09 | — | — | EP | claimed |
| WO-1990006975-A1 | NON-TIN-BASED, LOW TOXICITY ANTI-FOULING AGENTS | BATTELLE MEMORIAL INSTITUTE (US) | 1990-06-28 | — | — | WO | claimed |
| US-4183942-A | Insecticidal (β-phenyl-β-substituted-vinyl)cyclopropanecarboxylates | FMC CORPORATION (US) | 1980-01-15 | — | — | US | claimed |
| US-4160842-A | Insecticidal [β-(substituted-phenyl)vinyl]cyclopropanecarboxylates | FMC CORPORATION (US) | 1979-07-10 | — | — | US | claimed |
| US-4157397-A | RESISTANT TO PHOTOOXIDATIVE DEGRADATION | FMC CORPORATION (US) | 1979-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | OPRL1, OPRK1, OPRM1 | CYP3A4 277/4885FLT1 3163/4885AHR 3154/4885 |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | CNR1, CNR2, OPRL1 | CYP3A4 1129/4885FLT1 655/4885AHR 688/4885 |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | CNR1, CNR2, OPRL1 | CYP3A4 695/4885FLT1 851/4885AHR 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.